Genmab A/S (OTCMKTS:GNMSF – Get Free Report) shares rose 29.6% on Thursday. The company traded as high as $569.70 and last traded at $569.06. Approximately 39 shares changed hands during trading, a decline of 99% from the average daily volume of 2,784 shares. The stock had previously closed at $439.05.
Genmab A/S Stock Performance
The company has a market cap of $35.04 billion, a PE ratio of 44.63 and a beta of 0.79. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.46 and a quick ratio of 2.44. The business has a 50-day moving average of $360.98 and a 200 day moving average of $302.82.
Genmab A/S Company Profile
Genmab A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary technologies to create differentiated antibodies and antibody-drug conjugates designed to engage the immune system or target specific disease-related proteins.
Genmab’s technologies include the DuoBody platform for generating bispecific antibodies, as well as the HexaBody platform for developing antibodies with enhanced activity.
Featured Stories
- Five stocks we like better than Genmab A/S
- Constellation Energy’s Nuclear Expansion Gets a $5 Billion Opening, Not a Guarantee
- Plugging In: Vertiv Cashes In On AI Demand
- Visa’s Toll Booth Keeps Collecting, But the Price Is Rising
- Alphabet’s Cloud Is Paying Off—But the Bill for Building It Keeps Growing
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
